Assessment of quality of life on 4-year growth hormone therapy in Japanese patients with adult growth hormone deficiency: A post-marketing, multicenter, observational study.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this observational study publication.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

This multicenter, non-interventional, observational study in Japanese patients with severe AGHD was conducted from 1 October 2009 to 30 September 2014.

Patients with severe AGHD already receiving somatropin and somatropin-naïve patients were included.

How the Study Was Run

In design terms this was a multicenter study.

Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.

Demographic/clinical data were obtained from medical records or by patient recall.

What Was Measured

Topics PubMed links to this paper include Growth Disorders, Hormone Replacement Therapy, Human Growth Hormone, Product Surveillance, Postmarketing, Quality of Life and Recombinant Proteins.

Author keywords: Adult Hypopituitarism Questionnaire and Japanese adult growth hormone deficiency.

What This Means in Plain Language

The paper is a multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2017 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.